ASTRO 2022 | Genomic classifiers for prostate cancer risk statification

Omar Mian, MD, PhD, Cleveland Clinic, Cleveland, OH, discusses a study investigating the use of genomic classifiers for prostate cancer risk stratification to improve personalised treatment decision-making. The study assessed prostate cancer morphology compared with gene expression profile and found an association between aggressive disease and a higher risk score in terms of genomic classifiers. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.